Corbus Pharmaceuticals
Develops CRB-701 for oncology and CRB-913 for obesity.
Something off on this page? Send us feedback.
Profile
Develops clinical-stage candidates in oncology and obesity. The pipeline pairs CRB-701, a licensed Nectin-4-targeting antibody-drug conjugate, with CRB-913, an orally delivered peripherally restricted CB1 inverse agonist, and uses external service providers across development.
Develops clinical-stage therapies in oncology and obesity. CRB-701 is a Nectin-4-targeting antibody-drug conjugate for Nectin-4-expressing tumors, licensed from CSPC Megalith. FDA has granted the candidate Fast Track designations for head and neck squamous cell carcinoma and cervical cancer. CRB-913 is an orally delivered, peripherally restricted CB1 inverse agonist for obesity.
Clinical development relies on a small internal workforce with consultants, CROs, and other third parties supporting preclinical, clinical, manufacturing, and regulatory work. Neither lead program is commercial; the licensed pipeline follows unsuccessful Phase 3 studies of the earlier lenabasum program.
Company facts
Key statistics
Year to date +38.6% · Average volume (30d) 415.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 26, 2026 | H.C. Wainwright | Reiterate | Buy | $40 | $35 |
| Aug 13, 2026 | Mizuho Securities | Target | $44 | $33 | |
| May 22, 2026 | Mizuho Securities | Target | $39 | $44 | |
| May 12, 2026 | Jefferies | Target | $46 | $33 | |
| Oct 29, 2025 | Mizuho Securities | Target | $74 | $39 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$1.26 | −$1.81 | −43.7% | $1.1M | — | — | +1.78% |
| May 12, 2026Q1 FY26 | −$1.26 | −$1.23 | +2.4% | — | — | — | +6.30% |
| Mar 9, 2026Q4 FY25 | −$1.78 | −$1.25 | +29.8% | $1.7M | — | — | +5.13% |
| Nov 12, 2025Q3 FY25 | −$1.80 | −$1.90 | −5.6% | $1.1M | — | — | −1.07% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$15.6M | −$100.0K | $0 | $0 | −$49.0K | $0 | |
| Operating income | −$19.8M | −$19.2M | −$24.4M | −$22.0M | −$24.3M | −$36.2M | |
| Net income | −$17.0M | −$17.7M | −$23.3M | −$20.6M | −$23.0M | −$35.0M | |
| Diluted EPS | −$1.39 | −$1.44 | −$1.90 | −$1.54 | −$1.23 | −$1.81 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $881.7K · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $117.9M · Total debt $4.3M · Total assets $127.0M · Shareholders' equity $102.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 18.53M · Float 14.32M · 77.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP · 10 percent owner | 2.34M | 12.66% | Form 4 | Dec 15, 2025 |
| Aberdeen Group plc | 1.32M | 7.53% | 13G | Jan 16, 2026 |
| Octagon Investments Master Fund LP | 1.12M | 9.30% | 13G | Oct 11, 2024 |
| BlackRock, Inc. | 1.09M | 5.90% | 13G | Jul 27, 2026 |
| Yuval Cohen · director, officer: Chief Executive Officer | 157.3K | 0.85% | Form 4 | Aug 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Nishant C. Saxena | officer: Chief Business Officer | +2,600 | $9.63 |
| Aug 7, 2026 | Sean F. Moran | officer: Chief Financial Officer | −12,000 | $10.08 |
| Aug 7, 2026 | Yuval Cohen | director, officer: Chief Executive Officer | −17,000 | $10.08 |
| Jun 10, 2026 | John Kenneth Jenkins | director | −4,800 | $7.91 |
| Jun 10, 2026 | Anne Altmeyer | director | −2,412 | $7.91 |
Peers
- Pfizer
Commercial Nectin-4 ADC rival in urothelial cancer
- Eli Lilly
Marketed and pipeline obesity-drug rival across incretin therapies
- Novo Nordisk (ADR)
Global obesity-drug rival with injectable and oral Wegovy
- Viking Therapeutics
Phase 3 obesity-drug rival with injectable and oral VK2735
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals | $11.10 | +1.79% | $202.1M | — | — | — | — |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Viking Therapeutics | $32.24 | +0.31% | $3.75B | — | — | — | — |
| Median | 36.9 | 18.4 | 4.0 | +2.6% |